PF-Atlas › Clinical Trials › NCT05674994

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Methylprednisone/Prednisone · Phase 3

Registry ID
NCT05674994
Phase
Phase 3
Status
Recruiting
Drug / intervention
Methylprednisone/Prednisone
Sponsor
Fondation Hôpital Saint-Joseph
Start
2023-10-26
Enrollment
110
Locations
29

About this trial

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.

View NCT05674994 on ClinicalTrials.gov →

Explore related

All Methylprednisone/Prednisone trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05674994 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.